大分割放射治疗 (HFRT) 在许多常见癌症部位的使用越来越频繁。当放疗适用于软组织肉瘤（STS）时，传统的分割放疗治疗方案仍然是护理标准。本研究的目的是系统地回顾已发表的关于使用术前大分割放射治疗作为软组织肉瘤患者治疗范例的一部分的数据。在此，我们总结了在 STS 术前治疗中使用大分割放疗的当前证据。我们对前瞻性或回顾性收集的诊断为软组织肉瘤并接受 HFRT 治疗的患者进行了数据库搜索。检索中包括评估影响四肢或躯干的所有组织学亚型的软组织肉瘤的研究。文章由两名独立评审员筛选以纳入本次评审。记录并整理了选定研究中的患者、治疗、毒性和结果数据。本综述包含 25 篇文章。自 2020 年以来，已发表 9 项前瞻性试验。剂量分割范围为 25-40Gy（5 次）或 28-42.75Gy（8-15 次）。局部控制和总生存结果与传统分割放疗的历史数据一致。急性毒性和伤口并发症发生率符合可接受的结果。晚期毒性数据有限，需要更长时间的随访。所有研究的病理完全缓解率都令人鼓舞。越来越多的证据支持大分割在 STS 术前治疗中安全有效。本综述强调了可以进一步研究以优化软组织肉瘤术前治疗的潜在领域。版权所有 © 2024。由 Elsevier Inc. 出版。

Hypofractionated radiotherapy (HFRT) is being used more frequently for many common cancer sites. Conventionally fractionated radiotherapy treatment regimens have remained the standard of care when radiotherapy is indicated for soft tissue sarcoma (STS). The aim of this study is to systematically review published data on the use of pre-operative hypofractionated radiotherapy as part of a curative treatment paradigm in patients with soft tissue sarcoma. Herein we summarise current evidence for the use of hypofractionated radiotherapy in the pre-operative treatment of STS.We conducted a database search for prospectively or retrospectively collected data on patients with a diagnosis of soft tissue sarcoma treated with HFRT. Studies evaluating soft tissues sarcoma of all histological subtypes affecting extremities or trunk were included in the search. Articles were screened by two independent reviewers for inclusion in this review. Patient, treatment, toxicity and outcome data was recorded and collated from selected studies.25 articles are included in this review. Nine prospective trials have been published since 2020. Dose fractionations range from 25-40Gy in 5 fractions or 28-42.75Gy in 8-15 fractions. Local control and overall survival outcomes are consistent with historical data for conventionally fractionated radiotherapy. Acute toxicity and wound complication rates are in keeping with acceptable results. Late toxicity data is limited and requires longer follow up. Rates of pathological complete response are promising across all studies.There is a growing body of evidence supporting hypofractionation as safe and effective in the pre-operative treatment of STS. This review highlights potential areas that could be further investigated to optimise pre-operative treatment for soft tissue sarcoma.Copyright © 2024. Published by Elsevier Inc.